A placentaris vascular endothelial growth factor A és endoglin gének placentaris aktivitása a méhen belüli növekedési visszamaradással járó terhességekben az eutróf magzati növekedéssel járó terhességekhez képest fokozott. E jelenség kiindulópontjaként az irodalmi adatok a placentaris endoglin aktivitás fokozódását véleményezik, amely antiangiogén hatása révén méhlepényi funkciózavar, illetve krónikus magzati hypoxia kialakulásához vezet. Ez utóbbi hatására a méhlepényi vascular endothelial growth factor A – egyfajta kompenzációként – aktivitásfokozódást mutat, amely az érképződés stimulálása révén a vérkeringési viszonyok javítását célozza. Noha az anyai serum placental growth factor szint mind méhen belüli növekedési visszamaradás, mind praeeclampsia esetén értékes prediktor lehet, méhlepényi génje a placentaris vérkeringés szabályozásában – feltehetően – kevésbé vesz rész. Orv. Hetil., 2017, 158(16), 612–617.
Wollmann, H. A.: Intrauterine growth restriction: definition and etiology. Horm. Res., 1988, 49(Suppl. 2), 1–6.
Economides, D. L., Nicolaides, K. H.: Blood glucose and oxygen tension levels in small-for-gestational-age fetuses. Am. J. Obstet. Gynecol., 1989, 160, 385–389.
Magnusson, A. L., Powell, T., Wennergren, M., et al.: Glucose metabolism in the human preterm and term placenta of IUGR fetuses. Placenta, 2004, 25, 337–346.
Marconi, A. M., Cetin, I., Davoli, E., et al.: An evaluation of fetal glucogenesis in intrauterine growth-retarded pregnancies. Metabolism, 1993, 42, 860–864.
Gluckman, P. D., Harding, J. E.: The physiology and pathophysiology of intrauterine growth retardation. Horm. Res., 1997, 48(Suppl. 1), 11–16.
Sheikh, S., Satoskar, P., Bhartiya, D.: Expression of insulin-like growth factor-I and placental growth hormone mRNA in placentae: a comparison between normal and intrauterine growth retardation pregnancies. Mol. Hum. Reprod., 2001, 7, 287–292.
Arroyo, J. A., Winn, V. D.: Vasculogenesis and angiogenesis in the IUGR placenta. Semin. Perinatol., 2008, 32, 172–177.
Ahmed, A., Perkins, J.: Angiogenesis and intrauterine growth restriction. Baillieres Best Pract. Res. Clin. Obstet. Gynaecol., 2000, 14, 981–998.
Maulik, D., Frances Evans, J., Ragolia, L.: Fetal growth restriction: pathogenic mechanisms. Clin. Obstet. Gynecol., 2006, 49, 219–222.
Pardi, G., Marconi, A. M., Cetin, I.: Pathophysiology of intrauterine growth retardation: role of the placenta. Acta Paediatr. Suppl., 1997, 423, 170–172.
Turan, O. M., Turan, S., Baschat, A. A., et al.: Progression of Doppler abnormalities in intrauterine growth restriction. Ultrasound Obstet. Gynecol., 2008, 32, 160–167.
Chen, C. P., Bajoria, R., Aplin, J. D.: Decreased vascularization and cell proliferation in placentas of intrauterine growth-restricted fetuses with abnormal umbilical artery flow velocity waveforms. Am. J. Obstet. Gynecol., 2002, 187, 764–769.
Mayhew, T. M., Charnock-Jones, D. S., Kaufmann, P.: Aspects of human fetoplacental vasculogenesis and angiogenesis. III. Changes in complicated pregnancies. Placenta, 2004, 25, 127–139.
Ferrara, N.: VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer, 2002, 2, 795–803.
Gourvas, V., Dalpa, E., Konstantinidou, A., et al.: Angiogenic factors in placentas from pregnancies complicated by fetal growth restriction (review). Mol. Med. Rep., 2012, 6, 23–27.
Demir, R., Seval, Y., Huppertz, B.: Vasculogenesis and angiogenesis in the early human placenta. Acta Histochem., 2007, 109, 257–265.
Ferrara, N., Gerber, H. P., LeCouter, J.: The biology of VEGF and its receptors. Nat. Med., 2003, 9, 669–676.
Tammela, T., Enholm, B., Alitalo, K., et al.: The biology of vascular endothelial growth factors. Cardiovasc. Res., 2005, 65, 550–563.
Kotani, T., Sumigama, S., Tsuda, H., et al.: A case report of placental mesenchymal dysplasia with an increased VEGF-D expression. Placenta, 2012, 33, 888–891.
Otrock, Z. K., Makarem, J. A., Shamseddine, A. I.: Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol. Dis., 2007, 38, 258–268.
Shore, V. H., Wang, T. H., Wang, C. L., et al.: Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta, 1997, 18, 657–665.
Hood, J. D., Meininger, C. J., Ziche, M., et al.: VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol., 1998, 274, H1054–H1058.
Jackson, M. R., Walsh, A. J., Morrow, R. J., et al.: Reduced placental villous tree elaboration in small-for-gestational-age pregnancies: relationship with umbilical artery Doppler waveforms. Am. J. Obstet. Gynecol., 1995, 172, 518–525.
Teasdale, F.: Idiopathic intrauterine growth retardation: histomorphometry of the human placenta. Placenta, 1984, 5, 83–92.
Andraweera, P. H., Dekker, G. A., Roberts, C. T.: The vascular endothelial growth factor family in adverse pregnancy outcomes. Hum. Reprod Update, 2012, 18, 436–457.
Luttun, A., Brusselmans, K., Fukao, H., et al.: Loss of placental growth factor protects mice against vascular permeability in pathological conditions. Biochem. Biophys. Res. Commun., 2002, 295, 428–434.
Odorisio, T., Schietroma, C., Zaccaria, M. L., et al.: Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J. Cell Sci., 2002, 115, 2559–2567.
Rutland, C. S., Mukhopadhyay, M., Underwood, S., et al.: Induction of intrauterine growth restriction by reducing placental vascular growth with the angioinhibin TNP-470. Biol. Reprod., 2005, 73, 1164–1173.
Garza-Veloz, I., Castruita-De la Rosa, C., Cortes-Flores, R., et al.: No association between polymorphisms/haplotypes of the vascular endothelial growth factor gene and preeclampsia. BMC Pregnancy Childbirth, 2011, 11, 35.
Cerdeira, A. S., Karumanchi, S. A.: Angiogenic factors in preeclampsia and related disorders. Cold Spring Harb. Perspect. Med., 2012, 2(11), a006585.
Szentpéteri, I., Rab, A., Kornya, L., et al.: Gene expression patterns of vascular endothelial growth factor (VEGF-A) in human placenta from pregnancies with intrauterine growth restriction. J. Matern. Fetal Neonatal Med., 2013, 26, 984–989.
Gougos, A., Letarte, M.: Primary structure of endoglin; an RDG-containing glycoprotein of human endothelial cells. J. Biol. Chem., 1990, 265, 8361–8364.
Ten Dijke, P., Goumans, M., Pardali, E.: Endoglin in angiogenesis and vascular diseases. Angiogenesis, 2008, 11, 79–89.
Van Laake, L. W., van den Driesche, S., Post, S., et al.: Endoglin has a crucial role in blood cell-mediated vascular repair. Circulation, 2006, 114, 2288–2297.
Zhang, Y., Yang, Y., Hong, H.: Multimodality molecular imaging of CD105 (endoglin) expression. Int. J. Clin. Exp. Med., 2011, 4, 32–42.
Ten Dijke, P., Arthur, H. M.: Extracellular controll of TGF-beta signalling in vascular development and disease. Nat. Rev. Mol. Cell Biol., 2007, 8, 857–869.
Arthur, H. M., Ure, J., Smith, A. J., et al.: Endoglin, an ancillary TGF-beta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev. Biol., 2000, 217, 42–53.
Yinon, Y., Kingdom, J. C., Odutayo, A., et al.: Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction. Circulation, 2010, 122, 1846–1853.
Wallner, W., Sengenberger, R., Strick, R., et al.: Angiogenetic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin. Sci., 2007, 112, 51–57.
Asvold, B. O., Vatten, L. J., Romundstad, P. R., et al.: Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction. Am. J. Epidemiol., 2011, 173, 630–639.
Laskowska, M., Laskowska, K., Oleszczuk, J.: Endoglin in pregnancy complicated by fetal intrauterine growth restriction in normotensive and preeclamptic pregnant women: a comparison between preeclamptic patients with appropriate-for-gestational-age weight infants and heatlhy pregnant women. J. Matern. Fetal Neonatal Med., 2012, 25, 806–811.
Ramsay, J. E., Ferrell, W. R., Crawford, L., et al.: Divergent metabolic and vascular phenotypes in preeclampsia and intrauterine growth restriction. J. Hypertens., 2004, 22, 2177–2183.
Stepan, H., Krämer, T., Faber, R.: Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J. Clin. Endocrinol. Metab., 2007, 92, 2831–2834.
Yinon, Y., Nevo, O., Xu, J., et al.: Severe intrauterine growth restriction pregnancies have increased placental endoglin levels. Am. J. Pathol., 2008, 172, 77–85.
Szentpéteri, I., Rab, A., Kornya, L., et al.: Placental gene expression patterns of endoglin (CD105) in intrauterine growth restriction. J. Matern. Fetal Neonatal Med., 2014, 27, 350–354.
Jeyabalan, A., McGonigal, S., Gilmour, C., et al.: Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta, 2008, 29, 555–563.
Elhawary, T. M., El-Bendary, A. S., Demerdash, H.: Maternal serum endoglin as an early marker of preeclampsia in high risk patients. Int. J. Womens Health, 2012, 4, 521–525.
Maglione, D., Guerriero, V., Viglietto, G., et al.: Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene, 1993, 8, 925–931.
Torry, D. S., Hinrichs, M., Torry, R. J.: Determinants of placental vascularity. Am. J. Reprod. Immunol., 2004, 51, 257–268.
Weinstein, L.: Syndrome of hemolysis, elevated liver enzymes and low platelet count: a severe consequence of hypertension in pregnancy. Am. J. Obstet. Gynecol., 1982, 142, 159–167.
Dekker, G., Sibai, B.: Primary, secondary and tertiary prevention of preeclampsia. Lancet, 2001, 357, 209–215.
Sibai, B., Dekker, G., Kupferminc, M.: Preeclampsia. Lancet, 2005, 365, 785–799.
Roberts, D. J., Post, M.: The placenta in pre-eclampsia and intrauterine growth restriction. J. Clin. Pathol., 2008, 61, 1254–1260.
Khong, T., de Wolf, F., Robertson, W., et al.: Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and by small-for-gestational age infants. Br. J. Obstet. Gynecol., 1986, 93, 1049–1059.
Makrydimas, G., Sotiriadis, A., Savvidou, M., et al.: Physiological distribution of placental growth factor and soluble Flt-1 in early pregnancy. Prenat. Diagn., 2008, 28, 175–179.
Levine, R., Lam, C., Qian, C., et al.: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med., 2006, 355, 992–1005.
Poon, L. C., Zaragoza, E., Akolekar, R., et al.: Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11 to 13 weeks of gestation. Prenat. Diagn., 2008, 28, 1110–1115.
Gomez-Roig, M. D., Mazarico, E., Sabria, J., et al.: Use of placental growth factor and uterine artery Doppler pulsatility index in pregnancies involving intrauterine fetal growth restriction or preeclampsia to predict perinatal outcomes. Gynecol. Obstet. Invest., 2015, 80, 99–105.
Joó, J. G., Rigó, J. Jr., Börzsönyi, B., et al.: Placental gene expression of the placental growth factor (PlGF) in intrauterine growth restriction. J. Matern. Fetal Neonatal Med., 2016 Sep 5. 1–5. [Epub ahead of print]